Ypsomed continues on its path of growth
In the first half-year of the current business year 2016/17, the Ypsomed Group generated consolidated net sales of CHF 1…
In the first half-year of the current business year 2016/17, the Ypsomed Group generated consolidated net sales of CHF 1…
To deliver innovative care solutions, that improve the lives of people with diabetes, is the focus of the collaboration…
The Ypsomed Group will also be securing its position as a technology leader in the field of injection and infusion syste…
In the first half-year of 2015/16, the Ypsomed Group generated consolidated sales totalling CHF 157.8 million, CHF 9.3 m…
In business year 2014/15 Ypsomed Group posted consolidated sales of CHF 306.6 million, which represents an increase of 1…
The Ypsomed Group, the leading developer and manufacturer of injection systems for self-medication and a diabetes specia…
In the first half of the 2014/15 financial year, the Ypsomed Group generated consolidated sales totaling CHF 148.5 milli…
Burgdorf diabetes specialist Ypsomed can announce another success in the Injection Systems business segment: The British…
The issue of who is to succeed Simon Michel in Marketing & Sales has been resolved internally. The two business segments…
The Ypsomed Group succeeded in successfully implementing the turnaround strategy in the 2013/14 financial year, posting…